Obrixtamig

– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pelitecan (zoci) delivered standout data at AACR 2026, with a 62.5% confirmed intracranial ORR in SCLC patients with brain metastases, and clinically meaningful activity (38.2% confirmed ORR) across epNECs; registrational DLLEVATE trial ongoing with enrollment expected to complete in the first half of 2027 – Collaborations with Amgen and Boehringer Ingelheim to evaluate zoci in combination with tarlatamab in SCLC and obrixtamig in SCLC and other NECs, positioning zoci as a potential backbone therapy – ZL-1503 (IL-13/IL-31Rα) demonstrated rapid, durable dual-pathway activity in preclinical data presented at IMMUNOLOGY2026, supporting less frequent dosing and broad potential across atopic diseases, including asthma; Phase 1/1b study underway with initial data expected in 2026 – KarXT launch preparations are underway and TIVDAK remains under regulatory review; positive Phase 3 readouts for povetacicept in IgAN and elegrobart in TED providing additional growth opportunities for our regional business Conference call and webcast today, May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates. “We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “During the quarter, we made strong progress advancing zoci, with AACR data reinforcing its differentiated pro both SCLC and epNECs, collaborations with Amgen and Boehringer Ingelheim to evaluate zoci as a potential backbone therapy, and rapid enrollment in the registrational DLLEVATE study, which is on track to be fully enrolled in the first half of 2027. We also continue to advance our growing portfolio of global clinical programs, including ZL-1503 (IL-13/IL-31Rα) for atopic dermatitis. This reflects the strength of our R&D engine, which is designed to scale and deliver a pipeline of differentiated new products. At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth.” “We are deepening our presence in key markets to capitalize on underlying demand for VYVGART and are expanding our regional footprint as we prepare for the launch of KarXT in China in the second quarter,” said Josh Smiley, President and Chief Operating Officer of Zai Lab. “Supported by national guidelines and an addressable population of ~8 million schizophrenia patients, KarXT’s launch positions us to bring the first novel therapy in decades to this critical market, with potential NRDL inclusion next year. In addition, we anticipate a potential regulatory approval for TIVDAK this year, and with positive Phase 3 readouts for povetacicept and elegrobart, we have additional opportunities for future growth. Across all efforts, we remain focused on driving consistent execution throughout our commercial portfolio.” First Quarter 2026 Financial Results Total revenue was $99.6 million in the first quarter of 2026, compared to $106.5 million for the same period in 2025, representing a decrease of 6% y-o-y. Product revenue, net was $95.6 million in the first quarter of 2026, compared to $105.7 million for the same period in 2025, representing a 10% y-o-y decrease, 12% y-o-y decrease at constant exchange rate (CER). This decrease was primarily driven by decreased sales for ZEJULA, partially offset by increased sales for XACDURO and NUZYRA: – ZEJULA was $30.0 million in the first quarter of 2026, compared to $49.5 million for the same period in 2025. Sales declined due to a shift in hospital utilization patterns following volume-based procurement for generic olaparib. – VYVGART was $17.6 million in the first quarter of 2026, compared to $18.1 million for the same period in 2025. Sales declined primarily due to a pricing adjustment related to NRDL renewal. – XACDURO, was $8.6 million in the first quarter of 2026, compared to $1.1 million for the same period in 2025. Growth was driven by strong patient demand and expanding hospital adoption but was partially constrained by supply limitations. – NUZYRA was $16.3 million in the first quarter of 2026, compared to $15.1 million for the same period in 2025. This growth was supported by increased market coverage and penetration. Research and Development (R&D) expenses were $65.6 million in the first quarter of 2026, compared to $60.7 million for the same period in 2025. This increase was primarily due to increased clinical trial-related expenses and licensing fees. Selling, General and Administrative (SG&A) expenses were $65.1 million in the first quarter of 2026, compared to $63.4 million for the same period in 2025. This increase was primarily driven by higher general selling expenses. Loss from operations was $69.4 million in the first quarter of 2026, $51.9 million when adjusted to exclude certain non-cash expenses including depreciation, amortization, and share-based compensation. A reconciliation of loss from operations (GAAP) to adjusted loss from operations (non-GAAP) is included at the end of this release. Net loss was $51.0 million in the first quarter of 2026, or a loss per ordinary share attributable to stockholders of $0.05 (or loss per American Depositary Share (ADS) of $0.46), compared to a net loss of $48.4 million for the same period in 2025, or a loss per ordinary share of $0.04 (or loss per ADS of $0.45). These increases in net loss were primarily due to lower product revenue and higher research and development expenses, partially offset by foreign currency gains. Cash and cash equivalents, short-term investments, and current restricted cash totaled $761.3 million as of March 31, 2026, compared to $789.6 million as of December 31, 2025. Recent Corporate Updates In April 2026, we appointed Yizhe Wang, Ph.D., as Operating Partner, to strengthen Zai Lab’s commercial capabilities and execution. Dr. Wang brings extensive experience in global oncology and immunology commercial operations, having led commercial teams across China, the U.S., and the U.K. at GSK and Eli Lilly. Recent Pipeline Highlights Below are key product candidate updates since our last earnings release: Oncology Pipeline Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC) (formerly ZL-1310): – In April 2026, Zai Lab presented compelling clinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating that zoci delivers rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer (ES-SCLC) and brain metastases as measured by blinded independent assessment using mRANO-BM criteria, as well as promising data in patients with extrapulmonary neuroendocrine carcinomas (epNECs). SCLC with Brain Metastases : Zoci showed a 53.7% confirmed intracranial objective response rate (iORR) with 62.5% (10/16) at the 1.6 mg/kg dose, including complete responses. Notably, responses were observed in patients without prior brain radiotherapy (9/15, 60%), highlighting the net drug effect on the intracranial lesions. Zoci was well tolerated, with Grade ≥3 treatment-related adverse events (TRAEs) in 19.9% (27/136) of the overall population and in 16.4% (9/55) of patients who received 1.6mg/kg. epNECs: Encouraging activity was observed with a 38.2% confirmed objective response rate across epNEC tumors of different primary origins. The safety pro epNEC was consistent with that previously observed in SCLC with Grade ≥3 TRAEs in 15.2% of patients in Phase 1b. – In April 2026, Zai Lab announced a global clinical trial collaboration with Amgen to evaluate zoci in combination with Amgen’s IMDELLTRA ® (tarlatamab-dlle), a DLL3/CD3 bispecific T-cell engager (TCE), for ES-SCLC and a clinical collaboration with Boehringer Ingelheim to evaluate zoci in combination with obrixtamig, a DLL3/CD3 bispecific TCE, for SCLC and other NECs. Immunology, Neuroscience, and Infectious Disease Pipeline ZL-1503 (IL-13/IL-31Rα): In April 2026, Zai Lab announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings reinforce the potential of ZL-1503 to be a first-in-class treatment option for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases. A global Phase 1/1b study is ongoing and Zai Lab expects to report the first-in-human data from the global Phase 1 portion in the second half of 2026. Povetacicept (APRIL/BAFF): – IgA nephropathy (IgAN) : In March 2026, Zai Lab partner Vertex announced positive data from a pre-specified Week 36 interim analysis of the global Phase 3 RAINIER trial of pove in IgA nephropathy (IgAN). The trial met its primary objective, with povetacicept-treated patients achieving a 52.0% reduction from baseline in 24-hour urine protein to creatinine ratio (UPCR), representing a statistically significant and clinically meaningful 49.8% UPCR reduction versus placebo (p<0.0001). Povetacicept was generally safe and well tolerated. Zai Lab participated in the global Phase 3 study in Greater China. – Primary membranous nephropathy (pMN): Zai Lab partner Vertex has completed enrollment in the Phase 2 portion of the global pivotal Phase 2/3 OLYMPUS study and has initiated the Phase 3 portion. Zai Lab participated in the global study in Greater China. Elegrobart (anti-IGF-1R, subcutaneous): Zai Lab partner Viridian Therapeutics announced positive topline data in both REVEAL-1 and REVEAL-2, elegrobart’s two pivotal phase 3 clinical trials for active and chronic TED, respectively. Elegrobart was generally well tolerated across both studies. Zai Lab holds an exclusive license from Zenas BioPharma to develop and commercialize elegrobart in Greater China and is currently conducting a Phase 3 bridging study in the region. – REVEAL-1 in active TED: met its primary endpoint with a highly statistically significant treatment effect. Both elegrobart Q4W and Q8W treatment arms showed rapid onset of treatment effect and achieved clinically meaningful 54% and 63% proptosis responder rates, respectively, versus 18% placebo at week 24. The Q4W treatment arm additionally provided meaningful diplopia benefit to patients with active TED. – REVEAL-2 in chronic TED: met its primary endpoint with a highly statistically significant treatment effect. Both elegrobart Q4W and Q8W treatment arms achieved statistically significant and clinically meaningful 50% and 54% proptosis responder rates, respectively, versus 15% placebo at week 24. The Q4W treatment arm additionally provided meaningful diplopia benefit to patients with chronic TED. Anticipated Major Milestones in 2026 Expected Clinical Developments and Data Readouts Global Pipeline Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC) (formerly ZL-1310) First-Line ES-SCLC: Zai Lab to provide data readout from the Phase 1 study evaluating zoci combination therapy (with atezolizumab and/or chemotherapy) in the second half of 2026 and advance zoci into a registrational study in 2026 based on emerging data. Extrapulmonary NECs: Zai Lab to complete the enrollment for the global Phase 2 portion of the ongoing Phase 1b/2 study evaluating zoci in patients with selected solid tumors and advance into registrational development in 2026. ZL-1503 (IL-13/IL-31Rα) Zai Lab to provide the first-in-human data readout from the global Phase 1/1b study in 2026. Regional Pipeline Upcoming Potential NMPA Approvals TIVDAK (Tisotumab Vedotin, Tissue Factor ADC) in recurrent or metastatic cervical cancer following progression on or after chemotherapy Tumor Treating Fields (TTFields) in locally advanced pancreatic cancer Expected Data Readouts Efgartigimod (FcRn) Myositis: Zai Lab partner argenx to provide topline results from the global Phase 2/3 ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) in the third quarter of 2026. Zai Lab participated in the study in Greater China. Elegrobart (Anti-IGF-1R, subcutaneous) Zai Lab to complete the enrollment for the Phase 3 registrational study in China in the third quarter of 2026. Conference Call and Webcast Information Zai Lab will host a live conference call and webcast today, May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT). Listeners may access the live webcast by visiting the Company’s website at . Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): Registration link for dial-in: All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering. A replay will be available shortly after the call and can be accessed by visiting the Company’s website. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit or follow us at . Non-GAAP Measures In addition to results presented in accordance with GAAP, we disclose growth rates that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars. We have also presented a measure of adjusted loss from operations that adjusts GAAP loss from operations to exclude the impact of certain non-cash expenses including depreciation, amortization, and share-based compensation, which we refer to as “profitability.” These adjusted growth rates and adjusted loss from operations are non-GAAP measures. We believe that these non-GAAP measures are important for an understanding of the performance of our business operations and financial results and provide investors with an additional perspective on operational trends and greater transparency into our historical and projected operating performance. Although we believe the non-GAAP financial measures enhance investors’ understanding of our business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Zai Lab Forward-Looking Statements This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth, profitability, and cash flow); clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our profitability and timeline to profitability; our future financial and operating results; and financial guidance, including with respect to our capital allocation and investment strategy and our expected path to profitability. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “poised,” “positioned,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC’s website at . Zai Lab Limited Unaudited Condensed Consolidated Balance Sheets (in thousands of U.S. dollars ($), except for number of shares and per share data) March 31, 2026 December 31, 2025 Assets Current assets Cash and cash equivalents 651,316 679,573 Restricted cash, current 100,000 100,000 Short-term investments 10,000 10,000 Accounts receivable (net of allowance for credit losses of $16 and $31 as of March 31, 2026 and December 31, 2025, respectively) 54,069 106,116 Notes receivable 7,929 12,169 Inventories, net 85,961 74,745 Prepayments and other current assets 35,454 36,683 Total current assets 944,729 1,019,286 Restricted cash, non-current 1,117 1,116 Property and equipment, net 47,067 47,389 Operating lease right-of-use assets 17,585 19,152 Land use rights, net 2,868 2,853 Intangible assets, net 75,759 76,144 Deferred tax assets 3,444 3,390 Other non-current assets 3,168 3,054 Total assets 1,095,737 1,172,384 Liabilities and shareholders’ equity Current liabilities Accounts payable 126,169 141,608 Current operating lease liabilities 5,983 6,344 Short-term debt 213,819 204,530 Other current liabilities 47,011 63,684 Total current liabilities 392,982 416,166 Deferred income 28,627 27,333 Non-current operating lease liabilities 12,107 13,385 Other non-current liabilities 40 — Total liabilities 433,756 456,884 Commitments and contingencies Shareholders’ equity Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 1,118,835,190 and 1,113,822,550 shares issued as of March 31, 2026 and December 31, 2025, respectively; 1,110,232,620 and 1,106,389,340 shares outstanding as of March 31, 2026 and December 31, 2025, respectively) 7 7 Additional paid-in capital 3,357,826 3,343,469 Accumulated deficit (2,679,636 ) (2,628,620 ) Accumulated other comprehensive income 15,105 29,697 Treasury Stock (at cost, 8,602,570 and 7,433,210 shares as of March 31, 2026 and December 31, 2025, respectively) (31,321 ) (29,053 ) Total shareholders’ equity 661,981 715,500 Total liabilities and shareholders’ equity 1,095,737 1,172,384 Zai Lab Limited Unaudited Condensed Consolidated Statements of Operations (in thousands of $, except for number of shares and per share data) Three Months Ended March 31, 2026 2025 Revenues Product revenue, net 95,556 105,650 Collaboration revenue 4,055 837 Total revenues 99,611 106,487 Expenses Cost of product revenue (38,315 ) (38,452 ) Cost of collaboration revenue (20 ) (195 ) Research and development (65,591 ) (60,729 ) Selling, general, and administrative (65,070 ) (63,422 ) Loss from operations (69,385 ) (56,311 ) Interest income 6,447 8,606 Interest expenses (1,637 ) (1,187 ) Foreign currency gains 14,837 651 Other income (expense), net 162 (197 ) Loss before income tax (49,576 ) (48,438 ) Income tax expense (1,440 ) — Net loss (51,016 ) (48,438 ) Loss per share - basic and diluted (0.05 ) (0.04 ) Weighted-average shares used in calculating net loss per ordinary share - basic and diluted 1,107,390,590 1,080,825,300 Zai Lab Limited Unaudited Condensed Consolidated Statements of Comprehensive Loss (in thousands of $) Three Months Ended March 31, 2026 2025 Net loss (51,016 ) (48,438 ) Other comprehensive loss, net of tax of nil: Foreign currency translation adjustments (14,592 ) (1,212 ) Comprehensive loss (65,608 ) (49,650 ) Zai Lab Limited Non-GAAP Measures (unaudited) ($ in thousands) Growth on a Constant Exchange Rate (CER) Basis Three Months Ended March 31, Year over Year % Growth 2026 2025 As reported At CER* Product revenue, net 95,556 105,650 (10 )% (12 )% Loss from operations (69,385 ) (56,311 ) 23 % 22 % * The growth rates at CER were calculated assuming the same foreign currency exchange rates were in effect for the current and prior year period Reconciliation of Loss from Operations (GAAP) to Adjusted Loss from Operations (Non-GAAP) Three Months Ended March 31, 2026 2025 GAAP loss from operations (69,385 ) (56,311 ) Plus: Depreciation and amortization expenses 3,944 3,458 Plus: Share-based compensation 13,524 15,800 Adjusted loss from operations (51,917 ) (37,053 ) Contacts For more information: Investor Relations: Christine Chiou / Cyan Liu +1 (917) 886-6929 / +86 195 3130 8895 christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen +1 (415) 317-7255 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs Catalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies COVID-19 2026/2027 season variant-adapted vaccine development and commercial preparation underway Operational efficiency to be enhanced through manufacturing footprint consolidation , supporting strategic capital allocation to further advance its growing oncology pipeline toward commercialization First quarter 2026 revenues of €118.1 million 1 , net loss of €531.9 million (adjusted 2 net loss of €494.6 million), with diluted loss per share of €2.10 ($2.46 3 ) (adjusted 2 diluted loss per share of €1.95 ($2.28 3 )) Reaffirmed full year 2026 financial guidance and strong financial position continue to de-risk execution with cash, cash equivalents and security investments of €16.8 billion 4 Share repurchase program of up to $1.0 billion over twelve months planned Conference call and webcast scheduled for May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET) MAINZ, Germany, May 5, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress. “In the first quarter, we made substantial progress in executing towards our oncology strategy, highlighted by data presentations from our priority pan-tumor program pumitamig as well as our versatile antibody-drug conjugate portfolio. Simultaneously, we continue to broaden our clinical programs to include novel-novel combinations in order to inform the optimal set-up for registrational combination trials and maximize the potential of our pipeline,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech . “We will continue to focus on accelerating our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients living with cancer.” Financial Review for First Quarter 2026 in millions €, except per share data First Quarter 2026 First Quarter 2025 IFRS Results Adjusted Results 2 IFRS Results Adjusted Results 2 Revenues 118.1 118.1 182.8 182.8 Net loss (531.9) (494.6) (415.8) (430.8) Diluted loss per share (2.10) (1.95) (1.73) (1.79) Revenues for the first quarter of 2026 were €118.1 million, compared to €182.8 million for the comparative prior year period. The decrease was primarily driven by lower revenues of BioNTech’s COVID-19 vaccines. Research and development (“R&D”) expenses were €557.0 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. R&D expenses were mainly driven by higher expenses for the development of immuno-oncology (“IO”) and antibody-drug conjugate (“ADC”) programs, in particular pumitamig and gotistobart, as well as costs from operations of entities acquired during 2025, BioNTech China (previously Biotheus) and CureVac, and an impairment of an intangible asset. These effects were partly offset by lower R&D expenses related to the Company’s COVID‑19 vaccine collaboration with Pfizer Inc. (“Pfizer”). Adjusted R&D expenses were €527.1 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. For the first quarter of 2026, adjusted R&D expenses exclude the impairment of an intangible asset. Sales, general and administrative (“SG&A”) expenses 5 were €150.8 million for the first quarter of 2026, compared to €120.6 million for the comparative prior year period. The increase was mainly driven by the ongoing commercial build-up and the inclusion of operations of entities acquired in 2025, BioNTech China (previously Biotheus) and CureVac. These costs were partly offset by a reduction in external services. Net loss was €531.9 million for the first quarter of 2026, compared to a net loss of €415.8 million for the comparative prior year period. Adjusted net loss was €494.6 million for the first quarter of 2026, compared to an adjusted net loss of €430.8 million for the comparative prior year period. Diluted loss per share was €2.10 for the first quarter of 2026, compared to a diluted loss per share of €1.73 for the comparative prior year period. Adjusted diluted loss per share was €1.95 for the first quarter of 2026, compared to adjusted diluted loss per share of €1.79 for the comparative prior year period. Cash, cash equivalents and security investments as of March 31, 2026, were €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets. Shares outstanding as of March 31, 2026, were 252,884,261, excluding 6,143,226 shares held in treasury “Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations,” said Ramón Zapata, Chief Financial Officer at BioNTech . “We are committed to a diligent capital allocation strategy that empowers us to pursue our goal of evolving into a leading biopharmaceutical company with multiple oncology products by 2030.” Reaffirmed 2026 Financial Year Guidance 6 : Revenues for the 2026 financial year €2,000 – €2,300 m In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a competitive and dynamic market, where, as a result, lower revenues are expected. In Europe, the Company expects lower revenues as it defends its market share and begins managing the transition away from multi-year contracts. In Germany specifically, BioNTech recognizes direct sales of its COVID-19 vaccines as revenue. Hence, the anticipated declines in sales of COVID-19 vaccines in Germany will have a direct impact on the Company’s topline, whereas revenues outside of Germany only affect the Company’s topline as part of the 50% gross profit split with its partner Pfizer. Per the outlined partnership terms, revenues from the collaboration with Bristol Myers Squibb Company (“BMS”) in 2026 are expected to be broadly in line with 2025. Revenues from the pandemic preparedness contract with the German government and service businesses are expected to remain stable. Planned 2026 Financial Year Adjusted Expenses 6 : Adjusted R&D expenses €2,200 – €2,500 m Adjusted SG&A expenses 5 €700 – €800 m BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology, while remaining cost-disciplined. Strategic capital allocation will continue to foster innovation and be a key driver of the Company’s trajectory. As part of BioNTech’s strategy, the Company may continue to evaluate appropriate corporate development opportunities with the aim of driving sustainable long-term growth and creating future value. Planned Capital Return to Shareholders The Management Board and Supervisory Board expect to authorize a share repurchase program of BioNTech’s American Depositary Shares (“ADSs”), pursuant to which the Company may repurchase ADSs in the amount of up to $1.0 billion over the next twelve months. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The program is designed to enhance capital efficiency and support long-term value creation to execute BioNTech’s objective to become a multi-product company by 2030. Manufacturing Footprint Consolidation BioNTech continues to allocate capital strategically while optimizing capacities broadly to drive operational efficiency and sustainable value creation. To this end, BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts. BioNTech plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up to approximately 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027. For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale. BioNTech expects cost savings to ramp up over time, potentially reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 2029. 7 These savings are intended to support the Company’s capital allocation to further advance its growing oncology pipeline toward commercialization. BioNTech continues to ensure a robust drug supply via its established manufacturing network. No impact on commercial or clinical supply nor contractual obligations is expected as the affected sites will become underutilized or idle in the next 24 months. The full interim unaudited condensed consolidated financial statements can be found in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed today with the United States Securities and Exchange Commission (“SEC”) and available at . Endnotes 1 All numbers in this press release have been rounded. 2 In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of the Company’s business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at . While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company’s financial statements prepared in accordance with IFRS Accounting Standards. 3 Calculated applying the average foreign exchange rate for the three months ended March 31, 2026, as published by the German Central Bank (Deutsche Bundesbank). 4 As of March 31, 2026. 5 Sales, general and administrative expenses (“SG&A”) include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses. 6 Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at . 7 Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for Contract Development and Manufacturing Organizations (“CDMO”) use or transfer to other sites; and exclude exit costs, which will be recorded as incurred. 8 An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release. Select Oncology Pipeline Updates Next-Generation Immunomodulators and Combinations Pumitamig (BNT327/BMS986545) is an investigational bispecific immunomodulator combining PD-L1 8 checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with BMS. In the first quarter of 2026, the following pivotal trials evaluating pumitamig were initiated: A global Phase 3 clinical trial in patients with first-line triple-negative breast cancer (“TNBC”) (ROSETTA Breast-01; NCT07173751 ). A global Phase 2/3 clinical trial in first-line microsatellite stable colorectal cancer (“MSS-CRC”) (ROSETTA CRC-203; NCT07221357 ). A global Phase 2/3 clinical trial in first-line gastric cancer (ROSETTA Gastric-204; NCT07221149 ). A global Phase 3 clinical trial (ROSETTA Lung-201; NCT07361497 ) is being conducted to evaluate pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (“NSCLC”). A global Phase 3 clinical trial (ROSETTA Lung-202; NCT07361510 ) is being conducted to evaluate pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 ≥ 50% NSCLC. A global Phase 2/3 clinical trial (ROSETTA Lung-02; NCT06712316 ) is ongoing to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy in patients with first-line NSCLC. The Phase 3 part of the trial is currently recruiting. Data from the Phase 2 part of the trial are expected at the American Society of Clinical Oncology (“ASCO”) Annual Meeting 2026 (May 29 - June 2, 2026). Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma (“HCC”), second-line glioblastoma (“GBM”), first-line pancreatic ductal adenocarcinoma (“PDAC”) and first-line renal cell carcinoma (“RCC”) in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care. BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company’s proprietary assets. These trials will inform the dose selection for pumitamig and explore anti-tumor activity in multiple tumors for later-stage development. Multiple data readouts from these combinations are expected in 2026. In April 2026, BioNTech and Boehringer Ingelheim announced a clinical trial collaboration to assess the safety, tolerability and early clinical activity of pumitamig in combination with obrixtamig (BI 764532), Boehringer Ingelheim’s investigational DLL3/CD3 T‑cell engager, in extensive‑stage small cell lung cancer (“ES-SCLC”). Under the agreement, BioNTech will supply pumitamig and Boehringer Ingelheim will be the regulatory sponsor of the Phase 1b/2 trial. Gotistobart (BNT316/ONC-392) is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. (“OncoC4”). A global Phase 3 clinical trial (PRESERVE-003; NCT05671510 ) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC that progressed under previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment. In March 2026, updated data from the non-pivotal dose-confirmation stage, the first of two stages of the global Phase 3 clinical trial, were presented at the European Lung Cancer Congress (“ELCC”). Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard of care chemotherapy and a manageable safety pro patients with squamous NSCLC whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy. Based on current event accrual projections, interim data from the pivotal stage of the two-stage Phase 3 clinical trial are expected in 2026. In January 2026, gotistobart received Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of squamous NSCLC. In 2022, gotistobart received Fast Track Designation from the FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy. Antibody-Drug Conjugates Trastuzumab pamirtecan (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”). A Phase 1/2 clinical trial ( NCT05150691 ) is being conducted to evaluate trastuzumab pamirtecan in patients with advanced HER2-expressing tumors. A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with recurrent endometrial cancer (“EC”) is fully recruited. In April 2026, updated data from this trial were presented at the Society of Gynecologic Oncology (“SGO”) Annual Meeting. Trastuzumab pamirtecan demonstrated encouraging clinical efficacy across all HER2 expression levels and regardless of prior immunotherapy treatment. The safety pro patients with pretreated advanced or metastatic EC was manageable and generally consistent with that of HER2-targeted biologics. BioNTech and DualityBio plan to biologics license application (“BLA”) in 2026, subject to regulatory feedback. A Phase 3 trial (FERN-EC-01, NCT06340568 ) is being conducted to evaluate trastuzumab pamirtecan compared to investigator’s choice of chemotherapy in patients with advanced and HER2-expessing recurrent EC. A global Phase 3 clinical trial (DYNASTY-Breast02, NCT06018337 ) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer is ongoing. Based on current event accrual projections, data are expected in 2026. BNT324/DB-1311 is an ADC candidate targeting B7H3 that is being developed in collaboration with DualityBio. In February 2026, updated data from a Phase 1/2 clinical trial ( NCT05914116 ) were presented at the ASCO Genitourinary Cancers Symposium. BNT324/DB-1311 demonstrated durable efficacy in heavily pretreated metastatic castration-resistant prostate cancer (“mCRPC”) patients with no new safety signals reported. In April 2026, updated data from this trial were presented at the SGO Annual Meeting. BNT324/DB-1311 showed encouraging efficacy in previously treated cervical cancer and platinum resistant ovarian cancer (“PROC”) particularly in patients with treatment-naïve cervical cancer. The safety pro gynecologic malignancies was consistent with previous reports, and no new safety signals were observed. A Phase 3 clinical trial ( NCT07365995 ) to evaluate BNT324/DB-1311 compared to docetaxel in patients with mCRPC, is expected to initiate in 2026. Corporate and Commercial Update for the First Quarter 2026 and Post Period Events BioNTech and Pfizer developed, manufactured and delivered their variant-adapted COVID-19 vaccines, which have received multiple regulatory approvals, including full approvals, authorizations for emergency or temporary use or marketing authorizations, in more than 40 countries and regions. BioNTech is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2026/2027 vaccination season, pending approvals. In March 2026, BioNTech announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike. Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech’s Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech’s strategy. In March 2026, BioNTech published its Sustainability Report 2025. BioNTech recognizes the responsibility it has in how it is conducting its business and the impact its activities have on the economy, people, and the environment. The Sustainability Report 2025 outlines BioNTech's efforts, progress, key initiatives, and data as well as highlights in its corporate sustainability and responsibility over the past year. Upcoming Investor and Analyst Events BioNTech Annual General Meeting: May 15, 2026 BioNTech Second Quarter 2026 Financial Results and Corporate Update: August 4, 2026 Conference Call and Webcast Information BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET) to report its financial results and provide a corporate update for the first quarter of 2026. To access the live conference call via telephone, please register via this link . Once registered, dial-in numbers and a PIN number will be provided. The slide presentation and audio of the webcast will be available via this link . Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor section of the Company’s website at A replay of the webcast will be made available shortly after the closing of the call and archived on the Company’s website for 30 days following the call. About BioNTech BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech’s leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech’s expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s collaboration and licensing agreements, including BioNTech’s partnership with Bristol Myers Squibb; BioNTech’s expectations with respect to developments in law, public policy, and international trade; BioNTech’s estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech’s expectations for upcoming scientific and investor presentations; and BioNTech’s expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at . These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. CONTACTS Investor Relations Douglas Maffei, PhD Investors@biontech.de Media Relations Jasmina Alatovic Media@biontech.de Abbreviation Overview 1L First line 2L Second line ADC Antibody-drug conjugate B7H3 Also known as CD276, cluster of differentiation 276 BLA Biologics license application CTLA-4 Cytotoxic T-lymphocyte-associated protein EC Endometrial cancer ES-SCLC Extensive‑stage small cell lung cancer GBM Glioblastoma HCC Hepatocellular carcinoma HER2 (or HER3) Human epidermal growth factor receptor 2 (or 3) HPV16 Human papilloma virus 16 HR Hormone receptor IHC3+, 2+, 1+ Immunohistochemistry score 1+ (or 2+ or 3+) IO Immuno-oncology ISH-positive In-situ hybridization positive mCRPC Metastatic castration-resistant prostate cancer MSS-CRC Microsatellite stable colorectal cancer NSCLC Non-small cell lung cancer PDAC Pancreatic ductal adenocarcinoma PD-(L)1 Programmed cell death protein (death-ligand) 1 PROC Platinum resistant ovarian cancer RCC Renal cell carcinoma SCLC Small cell lung cancer TNBC Triple-negative breast cancer TROP2 Trophoblast cell-surface antigen 2 VEGF-A Vascular endothelial growth factor A Interim Condensed Consolidated Statements of Profit or Loss Three months ended March 31, 2026 2025 (in millions €, except per share data) (unaudited) (unaudited) Revenues 118.1 182.8 Cost of sales (71.4) (83.8) Research and development expenses (557.0) (525.6) Sales and marketing expenses (27.9) (13.7) General and administrative expenses (122.9) (106.9) Other operating expenses (46.8) (48.5) Other operating income 30.4 61.6 Operating loss (677.5) (534.1) Finance income 120.6 122.6 Finance expenses (11.2) (33.9) Loss before tax (568.1) (445.4) Income taxes 36.2 29.6 Net loss (531.9) (415.8) Loss per share Basic and diluted loss per share (2.10) (1.73) Interim Condensed Consolidated Statements of Profit or Loss (Adjusted Results) Adjusted Results (non-IFRS measures) 1 Three months ended March 31, 2026 2025 (in millions €, except per share data) (unaudited) (unaudited) Adjusted research and development expenses (527.1) (525.6) Adjusted other operating expenses (39.4) (48.5) Adjusted other operating income 30.4 46.6 Adjusted operating loss (640.2) (549.1) Adjusted loss before tax (530.8) (460.4) Adjusted net loss 2 (494.6) (430.8) Adjusted loss per share Adjusted basic and diluted loss per share (1.95) (1.79) 1 Certain adjusted results presented in this table are identical to BioNTech’s results under IFRS Accounting Standards. Reconciliation of all other adjusted results to the Company’s IFRS results can be found at the end of this press release and in BioNTech’s Report on Form 6-K for the period ended March 31, 2026 filed on May 5, 2026, which is available at . 2 Tax effects are not considered as part of our non-IFRS adjustments. Interim Condensed Consolidated Statements of Financial Position March 31 December 31, (in millions €) 2026 2025 Assets (unaudited) Non-current assets Goodwill 370.5 367.9 Other intangible assets 1,546.8 1,606.0 Property, plant and equipment 1,112.7 1,080.9 Right-of-use assets 205.5 210.2 Contract assets — 2.0 Other financial assets 2,279.9 2,554.2 Other non-financial assets 12.2 7.3 Deferred tax assets 14.7 13.5 Total non-current assets 5,542.3 5,842.0 Current assets Inventories 103.8 110.7 Trade and other receivables 539.2 924.2 Contract assets 8.9 8.1 Other financial assets 4,699.8 7,201.8 Other non-financial assets 176.6 173.8 Income tax assets 64.1 52.6 Cash and cash equivalents 9,939.4 7,675.4 Total current assets 15,531.8 16,146.6 Total assets 21,074.1 21,988.6 Equity and liabilities Equity Share capital 259.0 259.0 Capital reserve 2,468.2 2,473.3 Treasury shares (6.1) (7.7) Retained earnings 17,430.0 17,961.9 Other reserves (1,453.3) (1,462.3) Total equity 18,697.8 19,224.2 Non-current liabilities Lease liabilities, loans and borrowings 246.1 215.2 Other financial liabilities 92.0 94.9 Provisions 23.8 35.5 Contract liabilities 87.7 88.0 Other non-financial liabilities 108.8 104.2 Deferred tax liabilities 52.9 84.3 Total non-current liabilities 611.3 622.1 Current liabilities Lease liabilities, loans and borrowings 56.7 52.2 Trade payables and other payables 468.8 534.9 Other financial liabilities 77.5 351.7 Income tax liabilities 38.1 65.6 Provisions 167.0 145.3 Contract liabilities 758.5 754.9 Other non-financial liabilities 198.4 237.7 Total current liabilities 1,765.0 2,142.3 Total liabilities 2,376.3 2,764.4 Total equity and liabilities 21,074.1 21,988.6 Interim Condensed Consolidated Statements of Cash Flows Three months ended March 31, 2026 2025 (in millions €) (unaudited) (unaudited) Operating activities Net loss (531.9) (415.8) Income taxes (36.2) (29.6) Loss before tax (568.1) (445.4) Adjustments to reconcile loss before tax to net cash flows: Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets 121.3 42.8 Share-based payment expenses 22.8 22.1 Net foreign exchange differences 0.4 48.3 Gain on disposal of property, plant and equipment (0.1) (0.1) Finance income excluding foreign exchange differences (111.0) (122.6) Finance expense excluding foreign exchange differences 11.2 7.9 Government and similar grants (17.6) (14.5) Other non-cash income — (15.0) Working capital adjustments: Decrease in trade and other receivables, contract assets and other assets 431.1 520.7 Decrease in inventories 7.0 33.8 Decrease in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions (371.9) (981.6) Interest received and realized gains from cash and cash equivalents 86.6 118.6 Interest paid and realized losses from cash and cash equivalents (3.3) (3.1) Income tax paid, net (41.6) (12.2) Share-based payments (2.1) (3.6) Government and similar grants received 14.3 23.2 Net cash flows used in operating activities (421.0) (780.7) Investing activities Purchase of property, plant and equipment (56.8) (48.9) Proceeds from sale of property, plant and equipment 1.6 0.5 Purchase of intangible assets (22.1) (569.2) Acquisition of subsidiaries and businesses, net of cash acquired — (78.5) Investment in other financial assets (1,550.2) (2,507.7) Proceeds from maturity of other financial assets 4,278.1 4,450.6 Net cash flows from investing activities 2,650.6 1,246.8 Financing activities Proceeds from loans and borrowings 38.4 — Repayment of loans and borrowings (0.1) (4.5) Payments related to lease liabilities (11.9) (9.3) Net cash flows from / (used in) financing activities 26.4 (13.8) Net increase in cash and cash equivalents 2,256.0 452.3 Change in cash and cash equivalents resulting from exchange rate differences (3.4) (16.1) Change in cash and cash equivalents resulting from other valuation effects 11.4 (13.2) Cash and cash equivalents at the beginning of the period 7,675.4 9,761.9 Cash and cash equivalents as of March 31 9,939.4 10,184.9 Certain prior period lines were aggregated to conform to current period presentation. Non-IFRS Reconciliation Non-IFRS Reconciliation for the three months ended March 31, 2026 non-IFRS adjustments (unaudited) (in millions €, except per share data) IFRS Results Expenses and income from legal proceedings Impairment and reversal Employee-related expenses from restructuring Income from bargain purchase and income and expenses from divestiture related items Adjusted Results (unaudited) (unaudited) Research and development expenses (557.0) — 29.9 — — (527.1) Other operating expenses (46.8) — — 7.4 — (39.4) Operating loss (677.5) — 29.9 7.4 — (640.2) Loss before tax (568.1) — 29.9 7.4 — (530.8) Net loss 1 (531.9) — 29.9 7.4 — (494.6) Loss per share Basic and diluted loss per share (2.10) (1.95) 1 Tax effects are not considered as part of BioNTech's non-IFRS adjustments. Non-IFRS Reconciliation for the three months ended March 31, 2025 non-IFRS adjustments (unaudited) (in millions €, except per share data) IFRS Results Expenses and income from legal proceedings Impairment and reversal Employee-related expenses from restructuring Income from bargain purchase and income and expenses from divestiture related items Adjusted Results (unaudited) (unaudited) Other operating income 61.6 — — — (15.0) 46.6 Operating loss (534.1) — — — (15.0) (549.1) Loss before tax (445.4) — — — (15.0) (460.4) Net loss 1 (415.8) — — — (15.0) (430.8) Loss per share Basic and diluted loss per share (1.73) (1.79) 1 Tax effects are not considered as part of BioNTech's non-IFRS adjustments.